

Treadwell Therapeutics to Present at the Jefferies Virtual Healthcare Conference

New York, NY – June 1, 2020 – Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that members of the management team will provide a business overview and update at the Jefferies Virtual Healthcare Conference at 4:30 pm ET on Thursday, June 4, 2020.

A live webcast of the presentation will be available through the Company's website at <http://www.treadwelltx.com/>. Following the live webcast, an archived replay will be available on the Company's website.

About Treadwell Therapeutics

Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells' vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with cancer. The Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a potentially best-in-class TTK inhibitor, CFI-402257 ready for Phase 2, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1, which will enter the clinic in 2020. For more information, please visit www.treadwelltx.com.

Investor Contact:

Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com